Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA052151-07
Application #
2094621
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1990-05-01
Project End
1997-04-30
Budget Start
1995-05-12
Budget End
1997-04-30
Support Year
7
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
Medical University of South Carolina
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425

  Publications

Mc Clay, E F (2000) The effects of Delta(12)-PGJ(2) on malignant cells. Prostaglandins Other Lipid Mediat 62:75-90
McClay, E F; McClay, M E; Monroe, L et al. (2000) The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. Br J Cancer 83:16-21
Mc Clay, E F; Mc Clay, M E (1996) Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 23:744-53
Jekunen, A P; Hom, D K; Alcaraz, J E et al. (1994) Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells. Cancer Res 54:2680-7
McClay, E F; McClay, M E (1994) Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? J Clin Oncol 12:617-26
McClay, E F; Albright, K D; Jones, J A et al. (1993) Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53:1571-6
McClay, E F; Albright, K D; Jones, J A et al. (1993) Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer 55:1018-22
Mc Clay, E F; Mc Clay, M E; Albright, K D et al. (1993) Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation. Cancer 72:1914-8
McClay, E F; Albright, K D; Jones, J A et al. (1992) Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 52:6790-6